Melanie Peters
University of Marburg
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Melanie Peters.
Nature Genetics | 2002
Karl P. Schlingmann; Stefanie Weber; Melanie Peters; Lene N. Nejsum; Helga Vitzthum; Karin Klingel; Markus Kratz; Elie Haddad; Ellinor Ristoff; Dganit Dinour; Maria Syrrou; Søren Nielsen; Martin C. Sassen; Siegfried Waldegger; Hannsjörg W. Seyberth; Martin Konrad
Magnesium is an essential ion involved in many biochemical and physiological processes. Homeostasis of magnesium levels is tightly regulated and depends on the balance between intestinal absorption and renal excretion. However, little is known about specific proteins mediating transepithelial magnesium transport. Using a positional candidate gene approach, we identified mutations in TRPM6 (also known as CHAK2), encoding TRPM6, in autosomal-recessive hypomagnesemia with secondary hypocalcemia (HSH, OMIM 602014), previously mapped to chromosome 9q22 (ref. 3). The TRPM6 protein is a new member of the long transient receptor potential channel (TRPM) family and is highly similar to TRPM7 (also known as TRP-PLIK), a bifunctional protein that combines calcium- and magnesium-permeable cation channel properties with protein kinase activity. TRPM6 is expressed in intestinal epithelia and kidney tubules. These findings indicate that TRPM6 is crucial for magnesium homeostasis and implicate a TRPM family member in human disease.
The American Journal of Medicine | 2002
Melanie Peters; Nikola Jeck; Stephan C. Reinalter; Andreas Leonhardt; Burkhard Tönshoff; G.ünter Klaus; Martin Konrad; Hannsjörg W. Seyberth
PURPOSE Hypokalemic salt-losing tubulopathies (Bartter-like syndromes) comprise a set of clinically and genetically distinct inherited renal disorders. Mutations in four renal membrane proteins involved in electrolyte reabsorption have been identified in these disorders: the furosemide-sensitive sodium-potassium-chloride cotransporter NKCC2, the potassium channel ROMK, the chloride channel ClC-Kb, and the thiazide-sensitive sodium-chloride cotransporter NCCT. The aim of this study was to characterize the clinical features associated with each mutation in a large cohort of genetically defined patients. PATIENTS AND METHODS The phenotypic characteristics of 65 patients with molecular defects in NKCC2, ROMK, ClC-Kb, or NCCT were collected retrospectively. RESULTS ROMK and NKCC2 patients presented with polyhydramnios, nephrocalcinosis, and hypo- or isosthenuria. Hypokalemia was less severe in the ROMK patients compared with the NKCC2 patients. In contrast, NCCT patients had hypocalciuria, hypomagnesemia, and marked hypokalemia. While this dissociation of renal calcium and magnesium handling was also observed in some ClC-Kb patients, a few ClC-Kb patients presented with hypercalciuria and hypo- or isosthenuria. CONCLUSIONS ROMK, NKCC2, and NCCT mutations usually have uniform clinical presentations, whereas mutations in ClC-Kb occasionally lead to phenotypic overlaps with the NCCT or, less commonly, with the ROMK/NKCC2 cohort. Based on these results, we propose an algorithm for the molecular diagnosis of hypokalemic salt-losing tubulopathies.
Pediatric Research | 2000
Nikola Jeck; Martin Konrad; Melanie Peters; Stefanie Weber; Klaus E. Bonzel; Hannsjörg W. Seyberth
Gitelman syndrome is an inherited renal disorder characterized by impaired NaCl reabsorption in the distal convoluted tubule and secondary hypokalemic alkalosis. In clinical practice, it is distinguished from other hypokalemic tubulopathies by the presence of both hypomagnesemia and normocalcemic hypocalciuria. To date, only mutations in a single gene encoding the thiazide-sensitive NaCl cotransporter have been found as the molecular basis of GS. We describe three unrelated patients presenting with the typical laboratory findings of GS. Mutational analysis in these patients revealed no abnormality in the SLC12A3 gene. Instead, all patients were found to carry previously described mutations in the CLCNKB gene, which encodes the kidney-specific chloride channel ClC-Kb, raising the possibility of genetic heterogeneity. Review of the medical histories revealed manifestation of the disease within the first year of life in all cases. Clinical presentation included episodes of dehydration, weakness, and failure to thrive, much more suggestive of classic Bartter syndrome than of GS. The coexistence of hypomagnesemia and hypocalciuria was not present from the beginning. In the follow-up, however, a drop of both parameters below normal range was a consistent finding reflecting a transition from cBS to GS phenotype. The phenotypic overlap may indicate a physiologic cooperation of the apical thiazide-sensitive NaCl cotransporter and the basolateral chloride channel for salt reabsorption in the distal convoluted tubule.
Pflügers Archiv: European Journal of Physiology | 2002
Siegfried Waldegger; Nikola Jeck; Petra Barth; Melanie Peters; Helga Vitzthum; Konrad Wolf; Armin Kurtz; Martin Konrad; Hannsjörg W. Seyberth
Abstract. The term Bartter syndrome encompasses a heterogeneous group of autosomal recessive salt-losing nephropathies that are caused by disturbed transepithelial sodium chloride reabsorption in the distal nephron. Mutations have been identified in the NKCC2 (Na+-K+-2Cl–) cotransporter and ROMK potassium channel, which cooperate in the process of apical sodium chloride uptake, and ClC-Kb chloride channels, which mediate basolateral chloride release. Recently, mutations in barttin, a protein not related to any known ion transporter or channel, were described in BSND, a variant of Bartter syndrome associated with sensorineural deafness. Here we show that barttin functions as an activator of ClC-K chloride channels. Expression of barttin together with ClC-K in Xenopus oocytes increased ClC-K current amplitude, changed ClC-K biophysical properties, and enhanced ClC-K abundance in the cell membrane. Co-immunoprecipitation revealed a direct interaction of barttin with ClC-K. We performed in situ hybridization on rat kidney slices and RT-PCR analysis on microdissected nephron segments to prove co-expression of barttin, ClC-K1 and ClC-K2 along the distal nephron. Functional analysis of BSND-associated point mutations revealed impaired ClC-K activation by barttin. The results demonstrate regulation of a CLC chloride channel by an accessory protein and indicate that ClC-K activation by barttin is required for adequate tubular salt reabsorption.
Clinical Pharmacology & Therapeutics | 2001
Rolf M. Nüsing; Stephan C. Reinalter; Melanie Peters; Martin Kömhoff; Hannsjörg W. Seyberth
Patients with hyperprostaglandin E syndrome/antenatal Bartter syndrome typically have renal salt wasting, hypercalciuria with nephrocalcinosis, and secondary hyperaldosteronism. Antenatally, these patients have fetal polyuria, leading to polyhydramnios and premature birth. Hyperprostaglandin E syndrome/antenatal Bartter syndrome is accompanied by a pathologically elevated synthesis of prostaglandin E2, thought to be responsible for aggravation of clinical symptoms such as salt and water loss, vomiting, diarrhea, and failure to thrive. In this study administration of the cyclooxygenase‐2 (COX‐2) specific inhibitor nimesulide to patients with hyperprostaglandin E syndrome/antenatal Bartter syndrome blocked renal prostaglandin E2 formation and relieved the key parameters hyperprostaglandinuria, secondary hyperaldosteronism, and hypercalciuria. Partial suppression of serum thromboxane B2 synthesis resulting from platelet COX‐1 activity and complete inhibition of urinary 6‐keto‐prostaglandin F1α, reflecting endothelial COX‐2 activity, indicate preferential inhibition of COX‐2 by nimesulide. Amelioration of the clinical symptoms by use of nimesulide indicates that COX‐2 may play an important pathogenetic role in hyperprostaglandin E syndrome/antenatal Bartter syndrome. Moreover, on the basis of our data we postulate that COX‐2‐derived prostaglandin E2 is an important mediator for stimulation of the renin‐angiotensin‐aldosterone system in the kidney.
Acta Paediatrica | 2005
Martin Kömhoff; Ismail Tekesin; Melanie Peters; Andreas Leonhard; Hannsjörg W. Seyberth
Background: Neonates affected by hyperprostaglandin E2 syndrome (HPS) present with severe polyuria. Both urinary losses as well as prostaglandin synthesis inhibitors may precipitate acute renal failure (ARF). Aim: Our goal was to maintain euvolaemia by replacement of urinary losses. Patient: Our patient was born prematurely with a family history typical of HPS. Urinary salt and water losses and PGE2 excretion were determined in 2‐ to 4‐h intervals. Salt and water were replaced accordingly.
Journal of The American Society of Nephrology | 2001
Stefanie Weber; Linda Schneider; Melanie Peters; Joachim Misselwitz; Gabriele Rönnefarth; Michael Böswald; Klaus E. Bonzel; Tomáš Seeman; Tereza Šuláková; Eberhard Kuwertz-Bröking; Alojz Gregoric; Jean-Bernard Palcoux; Velibor Tasic; Friedrich Manz; Karl Schärer; Hannsjörg W. Seyberth; Martin Konrad
Kidney International | 2003
Melanie Peters; Saskia Ermert; Nikola Jeck; Christian Derst; Ulla Pechmann; Stefanie Weber; Karl P. Schlingmann; Hannsjoerg W. Seyberth; Siegfried Waldegger; Martin Konrad
Journal of The American Society of Nephrology | 2001
Stefanie Weber; Karl P. Schlingmann; Melanie Peters; Lene Niemann Nejsum; Søren Nielsen; Hartmut Engel; Karl-Heinz Grzeschik; Hannsjörg W. Seyberth; Hermann-Joseph Gröne; Rolf Nüsing; Martin Konrad
Saudi Journal of Kidney Diseases and Transplantation | 2003
Melanie Peters; Martin Konrad; Hannsjörg W. Seyberth